Literature DB >> 3051258

Cardiac rehabilitation exercise programme. Compliance and compliance-enhancing strategies.

N B Oldridge1.   

Abstract

Compliance-enhancing strategies in cardiac rehabilitation should be investigated only if it has been shown that the condition under consideration is an important cause of mortality and premature disability, that the intervention or therapy is effective, and that compliance with the intervention is poor. Coronary artery disease is the leading cause of death and premature disability in industrialized countries. Evidence from randomised controlled trials of supervised exercise rehabilitation after documentation of coronary artery disease suggests a reduction in fatal event rates, and an initial improvement in both exercise tolerance and psychosocial status, although these differences between experimental and control subjects are reduced over time. Poor compliance with supervised exercise programmes is a problem. This suggests that compliance enhancement with programmes of exercise rehabilitation for cardiac patients is an appropriate area of research. A number of issues recur in compliance research including the investigation of compliance-enhancing strategies in exercise rehabilitation. These relate to the specification of definition of compliance, the description of the experimental protocol or strategy, the selection and description of the sample to be studied, the randomisation of the sample, the selection of compliance measures, contamination and co-intervention, monitoring for decay, and various ethical issues. Compliance-enhancing strategies must be designed with these methodological issues in mind. These issues are discussed with specific reference to randomised controlled trials of compliance-enhancing strategies to cardiac exercise rehabilitation.

Entities:  

Mesh:

Year:  1988        PMID: 3051258     DOI: 10.2165/00007256-198806010-00005

Source DB:  PubMed          Journal:  Sports Med        ISSN: 0112-1642            Impact factor:   11.136


  35 in total

1.  REHABILITATION OF PATIENTS WITH CARDIOVASCULAR DISEASES. REPORT OF A WHO EXPERT COMMITTEE.

Authors:  R A BROWN
Journal:  World Health Organ Tech Rep Ser       Date:  1964

2.  Exercise Compliance: A New View for Public Health.

Authors:  R K Dishman
Journal:  Phys Sportsmed       Date:  1986-05       Impact factor: 2.241

3.  Cardiac rehabilitation after myocardial infarction. Combined experience of randomized clinical trials.

Authors:  N B Oldridge; G H Guyatt; M E Fischer; A A Rimm
Journal:  JAMA       Date:  1988-08-19       Impact factor: 56.272

Review 4.  Adherence to exercise.

Authors:  J E Martin; P M Dubbert
Journal:  Exerc Sport Sci Rev       Date:  1985       Impact factor: 6.230

5.  Relation of exercise to the recurrence rate of myocardial infarction in men. Ontario Exercise-Heart Collaborative Study.

Authors:  P A Rechnitzer; D A Cunningham; G M Andrew; C W Buck; N L Jones; T Kavanagh; N B Oldridge; J O Parker; R J Shephard; J R Sutton; A P Donner
Journal:  Am J Cardiol       Date:  1983-01-01       Impact factor: 2.778

6.  Effects of denial on mood, compliance, and quality of functioning after cardiovascular rehabilitation.

Authors:  P H Soloff
Journal:  Gen Hosp Psychiatry       Date:  1980-06       Impact factor: 3.238

Review 7.  Preventive use of exercise rehabilitation after myocardial infarction.

Authors:  N B Oldridge; N L Jones
Journal:  Acta Med Scand Suppl       Date:  1986

8.  Effects of a prescribed supervised exercise program on mortality and cardiovascular morbidity in patients after myocardial infarction. The National Exercise and Heart Disease Project.

Authors:  L W Shaw
Journal:  Am J Cardiol       Date:  1981-07       Impact factor: 2.778

9.  Cardiac rehabilitation after acute myocardial infarction. 9-year controlled follow-up study.

Authors:  O Román; M Gutierrez; I Luksic; E Chavez; A L Camuzzi; E Villalón; C Klenner; F Cumsille
Journal:  Cardiology       Date:  1983       Impact factor: 1.869

10.  Multiple risk factor intervention trial. Risk factor changes and mortality results. Multiple Risk Factor Intervention Trial Research Group.

Authors: 
Journal:  JAMA       Date:  1982-09-24       Impact factor: 56.272

View more
  8 in total

1.  Access to cardiac rehabilitation among South-Asian patients by referral method: a qualitative study.

Authors:  Keerat Grewal; Yvonne W Leung; Parissa Safai; Donna E Stewart; Sonia Anand; Milan Gupta; Cynthia Parsons; Sherry L Grace
Journal:  Rehabil Nurs       Date:  2010 May-Jun       Impact factor: 1.625

Review 2.  Compliance bias as a factor in longitudinal exercise research. Osteoporosis.

Authors:  N B Oldridge
Journal:  Sports Med       Date:  1992-02       Impact factor: 11.136

3.  Adherence of stem cell transplant recipients receiving glucocorticoid therapy to an exercise-based rehabilitation program.

Authors:  G Stephen Morris; Kevin E Brueilly; Janet S Scheetz; Marcos J de Lima
Journal:  Support Care Cancer       Date:  2011-12-28       Impact factor: 3.603

Review 4.  Standard and alternative adjunctive treatments in cardiac rehabilitation.

Authors:  J K Levy
Journal:  Tex Heart Inst J       Date:  1993

Review 5.  Adherence to exercise programmes. Recommendations.

Authors:  J I Robison; M A Rogers
Journal:  Sports Med       Date:  1994-01       Impact factor: 11.136

6.  Dyslipidemia Management for Secondary Prevention in Women with Cardiovascular Disease: What Can We Expect From Non-pharmacologic Strategies?

Authors:  Seamus Whelton; Grant V Chow; Dominique Ashen; Roger S Blumenthal
Journal:  Curr Cardiovasc Risk Rep       Date:  2012-10

7.  A novel approach to the issue of physical inactivity in older age.

Authors:  Anne Tiedemann; Leanne Hassett; Catherine Sherrington
Journal:  Prev Med Rep       Date:  2015-07-21

8.  Factors Predicting the Utilization of Center-Based Cardiac Rehabilitation Program.

Authors:  Lufei Young; Qi Zhang; Eric Lian; Kimberly Roberts; Neal Weintraub; Yanbin Dong; Haidong Zhu; Hongyan Xu; Pascha Schafer; Stephanie Dunlap
Journal:  Geriatrics (Basel)       Date:  2020-09-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.